In a devastating blow to the company and large B-cell lymphoma patients relapsed or refractory to CD19 CAR T-cell therapy, Cargo Therapeutics Inc. terminated the phase II study of its lead CD22 cell ...

Cargo Therapeutics discontinued a study evaluating firicabtagene autoleucel, an autologous CD22 chimeric antigen receptor (CAR) T-cell therapy for large B-cell lymphoma and the company’s lead ...

Safety concerns and disappointing results led Cargo to stop testing the treatment, cut 50% of its workforce and evaluate strategic alternatives.

The drug in question, called firicabtagene autoleucel or firi-cel, is an autologous CD22 CAR-T cell therapy that had been ...

CARGO elects to discontinue FIRCE-1, a Phase 2 clinical study of firicabtagene autoleucel (firi-cel)1; Company believes results do not support a ...

CAR T–focused biotech Cargo Therapeutics surprised and disappointed analysts when it announced that it would discontinue a ...

The changes will extend the company's cash runway, enabling it to advance a tri-specific CAR T-cell candidate and its allogeneic cell therapy platform.

Shares of Tectonic Therapeutic Inc. (NASDAQ:TECX) were trading at $55, up $29.28, or 113%, on positive interim data from the phase Ib acute hemodynamic trial of its lead product candidate, TX-45.

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...